Related Experiment Video
Updated: Jan 13, 2026
07:08
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
1.3K
RFC4 Drives Pancreatic Cancer Progression: Prognostic Relevance and Functional Evidence
Jae Woong Koh1, Seon-Joo Park2
1Department of Ophthalmology, College of Medicine, Chosun University, Gwangju, Republic of Korea.
Anticancer Research
|October 28, 2025
Summary
Replication Factor C subunit 4 (RFC4) is overexpressed in pancreatic cancer, driving tumor progression. Targeting RFC4 may offer a new therapeutic strategy for pancreatic adenocarcinoma.
Area of Science:
- Molecular biology
- Cancer research
- Genomics
Background:
- Replication Factor C (RFC) complex is crucial for DNA replication and repair.
- RFC subunits are implicated in various cancers, but their role in pancreatic cancer is unclear.
- RFC4's specific involvement in pancreatic adenocarcinoma requires investigation.
Purpose of the Study:
- To analyze the expression and clinical significance of RFC4 in pancreatic adenocarcinoma.
- To investigate the functional role of RFC4 in pancreatic cancer cell lines.
- To evaluate RFC4 as a potential prognostic biomarker and therapeutic target.
Main Methods:
- Bioinformatic analysis of RFC4 expression and survival correlation using GEPIA2.
- Functional assays including MTT, colony formation, cell cycle analysis, and Transwell assays.
- RFC4 knockdown using siRNA in MIA Paca-2 and PANC-1 pancreatic cancer cells.
Main Results:
- RFC4 is significantly overexpressed in pancreatic adenocarcinoma.
- Overexpression of RFC4 correlates with poorer overall survival.
- RFC4 knockdown inhibits cell proliferation, colony formation, migration, and invasion, inducing G1/S phase arrest.
Conclusions:
- RFC4 is strongly associated with pancreatic cancer progression.
- RFC4 may serve as a prognostic biomarker for pancreatic cancer.
- RFC4 represents a potential therapeutic target for pancreatic cancer treatment.
